Drugs / IO-108
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05508100 | Sep 2022 → Apr 2024 | neoplasm | Immune-Onc Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05054348 | Sep 2021 → Apr 2024 | cancer | Immune-Onc Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04524871 | Nov 2020 → Jul 2027 expected | liver cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2024-11-21 | Immune-Onc Therapeutics | Results Immune-Onc Therapeutics Announces Positive Results from Phase 1 Dose Escalation Study of IO-108 in Advanced Solid Tumors Published in the Journal for ImmunoTherapy of Cancer immune-onc.com ↗
In the IO-108 monotherapy cohort, the overall response rate was 9%, with one patient achieving a durable complete response (CR) for over two years. |
| 2023-04-14 | Immune-Onc Therapeutics | Results Immune-Onc Therapeutics to Present Encouraging Phase 1 Data for IO-108 at AACR Annual Meeting 2023 immune-onc.com ↗
Phase 1 data show encouraging clinical benefit for IO-108 as a monotherapy and when combined with pembrolizumab, suggesting potential to overcome resistance to T-cell checkpoint inhibitors |
| 2022-07-14 | Immune-Onc Therapeutics | Results Immune-Onc Therapeutics Announces Appointment of Christopher Whitmore as Chief Financial Officer and Provides Clinical Progress Update immune-onc.com ↗
Signals of clinical activity observed in multiple tumor types for IO-108 as a single agent and in combination with an anti-PD-1 |
| 2022-05-16 | Immune-Onc Therapeutics | Regulatory Immune-Onc Therapeutics Receives China Investigational New Drug (IND) Approval for the Phase 1 Study of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Solid Tumors immune-onc.com ↗
“NMPA’s timely acceptance and approval of the IND for IO-108 represents a remarkable milestone for the company,” said Charlene Liao, Ph.D., chief executive officer of Immune-Onc. |
| 2022-04-08 | Immune-Onc Therapeutics | Results Immune-Onc Therapeutics Makes Two Presentations of IO-108, a Novel Clinical-Stage Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the AACR 2022 Annual Meeting immune-onc.com ↗
IO-108 promotes innate and adaptive anti-cancer immunity in preclinical models, and it is well-tolerated to date in the ongoing Phase 1 study for the treatment of solid tumors |
All press releases naming this drug 11 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IO-108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05508100 ↗ |
| Route | Intravenous | “IO-108 will be administered at a dose 1800 mg by IV infusion on Day 1 of each 21 day cycle.” NCT04524871 ↗ |